830 related articles for article (PubMed ID: 31727409)
1. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
[TBL] [Abstract][Full Text] [Related]
2. Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH.
Harrison SA; Bashir M; Moussa SE; McCarty K; Pablo Frias J; Taub R; Alkhouri N
Hepatol Commun; 2021 Apr; 5(4):573-588. PubMed ID: 33860116
[TBL] [Abstract][Full Text] [Related]
3. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Harrison SA; Bedossa P; Guy CD; Schattenberg JM; Loomba R; Taub R; Labriola D; Moussa SE; Neff GW; Rinella ME; Anstee QM; Abdelmalek MF; Younossi Z; Baum SJ; Francque S; Charlton MR; Newsome PN; Lanthier N; Schiefke I; Mangia A; Pericàs JM; Patil R; Sanyal AJ; Noureddin M; Bansal MB; Alkhouri N; Castera L; Rudraraju M; Ratziu V;
N Engl J Med; 2024 Feb; 390(6):497-509. PubMed ID: 38324483
[TBL] [Abstract][Full Text] [Related]
4. Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life.
Younossi ZM; Stepanova M; Taub RA; Barbone JM; Harrison SA
Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1354-1361.e7. PubMed ID: 34329774
[TBL] [Abstract][Full Text] [Related]
5. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Rinella ME; Abdelmalek MF; Trotter JF; Paredes AH; Arnold HL; Kugelmas M; Bashir MR; Jaros MJ; Ling L; Rossi SJ; DePaoli AM; Loomba R
Lancet; 2018 Mar; 391(10126):1174-1185. PubMed ID: 29519502
[TBL] [Abstract][Full Text] [Related]
6. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Sanyal A; Charles ED; Neuschwander-Tetri BA; Loomba R; Harrison SA; Abdelmalek MF; Lawitz EJ; Halegoua-DeMarzio D; Kundu S; Noviello S; Luo Y; Christian R
Lancet; 2019 Dec; 392(10165):2705-2717. PubMed ID: 30554783
[TBL] [Abstract][Full Text] [Related]
7. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
[TBL] [Abstract][Full Text] [Related]
8. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis.
Harrison SA; Ratziu V; Anstee QM; Noureddin M; Sanyal AJ; Schattenberg JM; Bedossa P; Bashir MR; Schneider D; Taub R; Bansal M; Kowdley KV; Younossi ZM; Loomba R
Aliment Pharmacol Ther; 2024 Jan; 59(1):51-63. PubMed ID: 37786277
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
Harrison SA; Frias JP; Neff G; Abrams GA; Lucas KJ; Sanchez W; Gogia S; Sheikh MY; Behling C; Bedossa P; Shao L; Chan D; Fong E; de Temple B; Shringarpure R; Tillman EJ; Rolph T; Cheng A; Yale K;
Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1080-1093. PubMed ID: 37802088
[TBL] [Abstract][Full Text] [Related]
10. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis.
Kannt A; Wohlfart P; Madsen AN; Veidal SS; Feigh M; Schmoll D
Br J Pharmacol; 2021 Jun; 178(12):2412-2423. PubMed ID: 33655500
[TBL] [Abstract][Full Text] [Related]
11. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
Loomba R; Kayali Z; Noureddin M; Ruane P; Lawitz EJ; Bennett M; Wang L; Harting E; Tarrant JM; McColgan BJ; Chung C; Ray AS; Subramanian GM; Myers RP; Middleton MS; Lai M; Charlton M; Harrison SA
Gastroenterology; 2018 Nov; 155(5):1463-1473.e6. PubMed ID: 30059671
[TBL] [Abstract][Full Text] [Related]
12. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.
Harrison SA; Taub R; Neff GW; Lucas KJ; Labriola D; Moussa SE; Alkhouri N; Bashir MR
Nat Med; 2023 Nov; 29(11):2919-2928. PubMed ID: 37845512
[TBL] [Abstract][Full Text] [Related]
13. Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.
Newsome PN; Palmer M; Freilich B; Sheikh MY; Sheikh A; Sarles H; Herring R; Mantry P; Kayali Z; Hassanein T; Lee HM; Aithal GP;
J Hepatol; 2020 Aug; 73(2):231-240. PubMed ID: 32234329
[TBL] [Abstract][Full Text] [Related]
14. Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study.
Loomba R; Lawitz EJ; Frias JP; Ortiz-Lasanta G; Johansson L; Franey BB; Morrow L; Rosenstock M; Hartsfield CL; Chen CY; Tseng L; Charlton RW; Mansbach H; Margalit M
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):120-132. PubMed ID: 36521501
[TBL] [Abstract][Full Text] [Related]
15. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.
Harrison SA; Abdelmalek MF; Neff G; Gunn N; Guy CD; Alkhouri N; Bashir MR; Freilich B; Kohli A; Khazanchi A; Sheikh MY; Leibowitz M; Rinella ME; Siddiqui MS; Kipnes M; Moussa SE; Younes ZH; Bansal M; Baum SJ; Borg B; Ruane PJ; Thuluvath PJ; Gottwald M; Khan M; Chen C; Melchor-Khan L; Chang W; DePaoli AM; Ling L; Lieu HD
Lancet Gastroenterol Hepatol; 2022 Jul; 7(7):603-616. PubMed ID: 35325622
[TBL] [Abstract][Full Text] [Related]
16. Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH).
Luong XG; Stevens SK; Jekle A; Lin TI; Gupta K; Misner D; Chanda S; Mukherjee S; Williams C; Stoycheva A; Blatt LM; Beigelman LN; Symons JA; Raboisson P; McGowan D; Vandyck K; Deval J
PLoS One; 2020; 15(12):e0240338. PubMed ID: 33306682
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.
Cusi K; Alkhouri N; Harrison SA; Fouqueray P; Moller DE; Hallakou-Bozec S; Bolze S; Grouin JM; Jeannin Megnien S; Dubourg J; Ratziu V
Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):889-902. PubMed ID: 34560015
[TBL] [Abstract][Full Text] [Related]
18. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.
Middleton MS; Heba ER; Hooker CA; Bashir MR; Fowler KJ; Sandrasegaran K; Brunt EM; Kleiner DE; Doo E; Van Natta ML; Lavine JE; Neuschwander-Tetri BA; Sanyal A; Loomba R; Sirlin CB;
Gastroenterology; 2017 Sep; 153(3):753-761. PubMed ID: 28624576
[TBL] [Abstract][Full Text] [Related]
19. Role of Resmetirom, a Liver-Directed, Thyroid Hormone Receptor Beta-Selective Agonist, in Managing Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.
Dutta D; Kamrul-Hasan ABM; Mondal E; Nagendra L; Joshi A; Bhattacharya S
Endocr Pract; 2024 May; ():. PubMed ID: 38697306
[TBL] [Abstract][Full Text] [Related]
20. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.
Ratziu V; Rinella ME; Neuschwander-Tetri BA; Lawitz E; Denham D; Kayali Z; Sheikh A; Kowdley KV; Desta T; Elkhashab M; DeGrauw J; Goodwin B; Ahmad A; Adda N
J Hepatol; 2022 Mar; 76(3):506-517. PubMed ID: 34740705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]